SynAct Pharma AB's book value per share for the quarter that ended in Mar. 2024 was kr4.28.
During the past 12 months, SynAct Pharma AB's average Book Value Per Share Growth Rate was -49.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 97.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 54.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of SynAct Pharma AB was 97.10% per year. The lowest was -26.80% per year. And the median was 7.30% per year.
SynAct Pharma AB's current price is kr7.055. Its book value per share for the quarter that ended in Mar. 2024 was kr4.28. Hence, today's PB Ratio of SynAct Pharma AB is 1.65.
During the past 8 years, the highest P/B Ratio of SynAct Pharma AB was 3779.32. The lowest was 0.00. And the median was 0.00.
SynAct Pharma AB Book Value per Share Historical Data
The historical data trend for SynAct Pharma AB's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SynAct Pharma AB's Book Value per Share
For the Biotechnology subindustry, SynAct Pharma AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynAct Pharma AB's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where SynAct Pharma AB's PB Ratio falls into.
SynAct Pharma AB Book Value per Share Calculation
SynAct Pharma AB's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
SynAct Pharma AB (OSTO:SYNACT) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
SynAct Pharma AB Book Value per Share Related Terms
Thank you for viewing the detailed overview of SynAct Pharma AB's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
SynAct Pharma AB (OSTO:SYNACT) Business Description
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:SYNACT has been successfully added to your 